Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | PPIA | P62937 | 1/20 | 0.31 |
| ▸ | FABP7 | O15540 | 1/20 | 0.30 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
| ▸ | EDNRB | P24530 | 1/20 | 0.30 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.30 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960620 | 0.81 | DPP4 (0.37) | TTRPDK2TSHRKMT2APPIA | |
| SCHEMBL9960712 | 0.74 | TTR (0.36) | TTRKMT2AEDNRBEDNRAMEN1 | |
| SCHEMBL9960689 | 0.74 | DPP4 (0.35) | PDK2KMT2APPIAFABP7FABP5 | |
| SCHEMBL9960591 | 0.74 | KMT2A (0.33) | TTRKMT2AMEN1 | |
| SCHEMBL9961055 | 0.71 | ATM (0.34) | TSHRKMT2AMEN1POLB | |
| SCHEMBL9960633 | 0.71 | FABP3 (0.36) | FABP5GAA | |
| SCHEMBL2457029 | 0.69 | ALDH1A1 (0.43) | KMT2AMEN1POLBGAA | |
| SCHEMBL9960784 | 0.69 | MEN1 (0.37) | KMT2AFABP7FABP5EDNRBEDNRA | |
| SCHEMBL9960663 | 0.68 | HTT (0.44) | KMT2AMEN1POLB | |
| SCHEMBL9961060 | 0.68 | MEN1 (0.42) | KMT2AEDNRBEDNRAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130331446-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-12-12 | — | — | US | claimed |
| EP-2655312-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | claimed |
| WO-2012083954-A1 | 3-ACYL-INGENOLS II | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | claimed |
| US-9656945-B2 | 3-acyl-ingenols II | LEO LABORATORIES LIMITED (IE) | 2017-05-23 | — | — | US | disclosed |
| US-20130331446-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-12-12 | — | — | US | disclosed |
| EP-2655312-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012083954-A1 | 3-ACYL-INGENOLS II | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331446-A1 | 3-ACYL-INGENOLS II | IL33, CXCL8, MMP8 | TTR 4086/4885PDK2 2357/4885TSHR 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.